Clinical trials: PET-CT
Prostate Cancer
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
This is a single arm, open label study of up to 24 prostate cancer patients scheduled for prostatectomy and/or pelvic lymph node dissection.
- Trial name
- NCT01615406
- Testing
- 99mTc MIP 1404
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Estrogen Receptor Positive Breast Cancer, Breast Neoplasm
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer [18F]fluoroestradiol (FES).
- Conditions
- Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
- Trial name
- NCT02409316
- Testing
- [18F]FES
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
Medullary Thyroid Cancer
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer
To assess the diagnostic accuracy of 18F-Fluorocholine PET/CT for the detection of medullary thyroid cancer in patients with primary and recurrent disease.
- Trial name
- NCT03643055
- Testing
- 18F-fluorocholine PET/CT
- Where
- Slovenia
- Volunteers
- 80 people
- Sponsor
- University Medical Centre Ljubljana
Prostate Cancer
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b Sponsor: MidLantic Urology…
- Trial name
- NCT05799248
- Testing
- rhPSMA-7.3 (18F)
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- MidLantic Urology
Esophageal Neoplasms, Gastric Neoplasms Malignant
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
The goal of this phase II clinical trial is to improve the selection of patients with solid tumors who would benefit from effective treatment with HER2 targeted drugs.
- Conditions
- Esophageal Neoplasms, Gastric Neoplasms Malignant, Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT05619016
- Testing
- [68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2 expression
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- Karolinska University Hospital
Gastroenteropancreatic Neuroendocrine Tumors
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan.
- Trial name
- GaIN (NCT02078843)
- Testing
- Gallium-68-DOTATATE PET/CT (index test), Indium-111-Octreoscan (standard test)
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Fibrosis (Morphologic Abnormality)
FAPI-74 PET/CT in Adults With Fibrosis
This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast Activating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety of medical conditions where fibrosis is believed to…
- Trial name
- NCT06413355
- Testing
- [F-18]-FAPI-74
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer Metastatic
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
Tumor bone metastasis refers to the metastasis of malignant tumors to the bone through lymph, blood or direct invasion to generate daughter tumors, which is the most common bone tumor.
- Trial name
- NCT05627778
- Testing
- 68Ga-PSMA-11, 68Ga-P15-041
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Covid19, Endothelial Dysfunction
RGD PET/CT Imaging in COVID-19 Patients
Aim: We aim to evaluate αvβ3 integrin expression in proven COVID-19 infected patients with indicative findings on routine contrast-enhanced CT using [68Ga]Ga-DOTA-(RGD)2.
- Conditions
- Covid19, Endothelial Dysfunction, PET Imaging
- Trial name
- NCT04596943
- Testing
- [68Ga]Ga-DOTA-(RGD)2 PET/CT
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Bacterial Infections
11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the…
- Trial name
- NCT03424525
- Testing
- 11C-Trimethoprim
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Amyotrophic Lateral Sclerosis
Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a rare neurodegenerative disease resulting in loss, primarily, of the motor neurons in the motor cortex, brainstem and spinal cord.
- Trial name
- NCT05974579
- Testing
- 89Zr-DFO-AP-101
- Where
- Canada
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuroendocrine Tumor, Neuroblastoma
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and…
- Conditions
- Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT05069220
- Testing
- 18F-MFBG, 68Ga-Dotatate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Diffuse Large B-cell Lymphoma
Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL
The aim of this study is to optimize the number of cycles of R-CHOP in patients with diffuse large B-cell lymphoma based on the interim results of PET/CT.
- Trial name
- NCT01804127
- Testing
- R-CHOP
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Fudan University
Cardiac Sarcoidosis, Myocardial Inflammation
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
The investigators will evaluate the detection of cardiac sarcoidosis or inflammation using 18F-FSPG PET/MRI (or PET/CT for participants with metal implants).
- Trial name
- NCT03103490
- Testing
- 18F-FSPG
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Autoimmune Disease
18F-FDG PET/CT for IgG4-Related Disease
This is an open-label study to investigate the diagnostic performance of 18F-FDG PET/CT (positron emission tomography/computed tomography) in evaluation of patients with IgG4-related disease.
- Trial name
- NCT01665196
- Testing
- 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Bone Metastases
Validation of Whole Body PET/CT Foundation Model
Prospective multicenter study to validate the diagnostic performance of whole body PET/CT foundation model for bone lesion detection
- Trial name
- NCT07196995
- Volunteers
- 180 people
- Sponsor
- Shanghai 6th People's Hospital
Invasive Fungal Infections
Usefulness of PET-CT for Invasive Fungal Infection
The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management.
- Trial name
- PETIFI (NCT05688592)
- Testing
- PET-CT
- Where
- 14 sites in Spain
- Volunteers
- 224 people
- Sponsor
- Puerta de Hierro University Hospital
Known CAD, or Intermediate-high Pretest Likelihood for CAD
Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)
Three main clinical outcomes will be assessed: 1. Post-test resource utilization as assessed by referral rate to catheterization within 90-days of the index study; 2.
- Trial name
- SPARC (NCT00321399)
- Where
- 41 sites in United States, Canada
- Volunteers
- 3,019 people
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.